1Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study % M; \& B& C% Uhttp://circheartfailure.ahajournals.org/content/6/4/711.long 7 F- M: S( e8 h! _2，Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) http://circheartfailure.ahajournals.org/content/7/1/51.long , @) Q$ B4 a1 V! ]) |# k3，Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist. U; u( c; S/ e" T% Zhttp://www-ncbi-nlm-nih-gov.ezpr ... Receptor+Antagonist7 K9 C9 j9 n, E" }! b A2 ]( p 作者: wagumaxida 时间: 2014-5-29 09:31